Substance Use Disorder

Ketamine is relatively new to the average American. What can you share with them as a mental health clinician?

From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.

Here’s how having a clear understanding of the services different crisis stabilization units provide can help communities serve the unique needs of each individual in crisis without unnecessarily restrictive or intensive levels of care.

The experts weighed in on a wide variety of psychiatric issues for the April 2023 issue of Psychiatric Times.

From to co-occurring substance use and eating disorders to treatment options for OCD, here are highlights from the week in Psychiatric Times.

The new criteria have been updated to increase flexibility and provide greater clarity around standards for behavioral health clinicians.

What does existing research say about the connection between substance use disorders and eating disorders?

From over-the-counter naloxone to the true connection between gun violence and mental illness, here are highlights from the week in Psychiatric Times.

Psychiatric Times’ Substance Use Section Editor weighs in on the FDA approval of the first naloxone product for nonprescription use.

From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.

The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients.

One doctor’s experience with patient suicide.

Patients with serious mental illness and substance use disorders are expected to be particularly affected by these changes.

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

A patient loss does not undo or discard the multitude of meaningful life changing and life preserving work done.

Revisiting the CME articles featured in Psychiatric Times in 2022.

While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence. Learn more in this CME article.

What are the most pertinent drug trends to be aware of in 2023?

We may be one step closer to nonprescription naloxone.

In this CME article, explore the mental health consequences associated with the COVID-19 pandemic as well as the potential role for complementary and alternative approaches.

What is recovery?

From traumatic brain injury to the dangers of excessive social media usage, here are highlights from the week in Psychiatric Times.

Comorbid SUD and ADHD is associated with more severe illness. What do we understand about these comorbid conditions and what do we still need to learn?

Opioid use, addiction, and overdose in youth continue to increase. What can be done?

The experts weighed in on a wide variety of psychiatric issues for the September 2022 issue of Psychiatric Times.

The NCCHC and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.

Contingency management is an effective behavior change technique commonly used to treat substance use disorders.

Suicide Prevention Week is September 4-10. Are you ready?